INTRODUCTION
The spleen is a secondary lymphoid organ that is essential in the immune response against blood-borne antigens. Hematopoiesis in the spleen is mainly restricted to the production of erythrocytes, although hematopoiesis can be triggered at times of stress or upon ablation of bone marrow.
1 A small number of HSCs can migrate through the blood and lymphatic system to enter the spleen and other tissues. 2, 3 However, it is not yet known whether hematopoietic stem cells in the steady-state spleen can self-renew and differentiate into a specific lineage of hematopoietic cells.
Human and murine spleens are very similar, but minor structural differences in the organization of the white pulp are evident. The human spleen differs in that it contains a perifollicular region external to the marginal zone in the red pulp, which is absent in murine spleen. 4 In general, human and murine spleens both contain equivalent lymphoid and myeloid subsets with similar functions. The splenic microenvironment also supports development of dendritic and myeloid cells from bone marrow-derived progenitors that enter the spleen through blood.
Dendritic cell (DC) subsets in the murine spleen have been broadly classified as conventional DCs (cDCs) and plasmacytoid DCs (pDCs), and the cDC population can be further divided into two subsets: CD8 1 cDCs and CD8 2 cDCs. CD8
2 cDCs are capable of inducing a CD4 1 T-cell response with production of inflammatory cytokines, 5 while the CD8 1 cDC subset is superior in cross-presenting antigen to CD8 1 T cells. 6 pDCs are the major producers of type I interferon. 7 Previously, this lab identified a novel splenic dendritic-like cell type called L-DCs in murine spleen with high potential to induce CD8 1 T-cell responses but with no capacity to induce CD4 1 T-cell responses. 8, 9 Murine L-DCs are distinguishable by very high endocytic capacity and a lack of MHC-II expression.
Recent studies have shown that these same cells can be generated through in vitro hematopoiesis when murine spleen-or bone marrow-derived hematopoietic stem/progenitor cells are cocultured with the splenic stromal cell line 5G3. [10] [11] [12] [13] [14] The LDCs produced are functionally distinct in their ability to activate CD8
1 but not CD4 1 T cells. Currently, L-DCs are thought to reflect a tissue-specific APC derived from progenitors endogenous to spleen. 15 The currently available evidence supports the possible role of L-DCs in antigen presentation of bloodborne antigens for CD8 1 T-cell activation. DC development in the human spleen has not been as extensively studied as it has in the murine spleen. In humans, DC subsets have been investigated mainly in blood due to greater accessibility of cells. Information about DC subsets in the human spleen has been limited by tissue availability. Recently, Mittag and colleagues 20 identified the same four subsets of DC in human spleen and showed that they resemble subsets that were previously identified in human peripheral blood. However, the presence of a human equivalent of the L-DC subset described in murine spleen has not yet been investigated. Here, human spleens were analyzed for DC and monocyte subsets using antibody staining and flow cytometric analysis. Human spleens were also tested for the presence of L-DC progenitors by coculturing splenocytes with the murine 5G3 splenic stromal line which supports the hematopoiesis of murine splenocytes. Cells produced in cocultures were phenotypically and functionally characterized, and compared with murine L-DCs.
MATERIALS AND METHODS

Splenic stromal cultures
The 5G3 splenic stromal line supports hematopoiesis in cocultured bone marrow and splenocytes. [27] [28] [29] The 5G3 stromal cells were maintained by scraping up adherent cells to passage every 3-4 days. Stromal cells were cultured at 37uC in 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 4 mg/ml glucose, 6 mg/ml folic acid, 36 mg/ml L-asparagine, 116 mg/ml L-asparagine hydrochloric acid, to which was added 10% fetal calf serum, 5310
24 M 2-mercaptoethanol, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 100 U/ml penicillin and 100 mg/ml streptomycin (sDMEM).
Preparation of human splenocytes
Fresh and/or cryopreserved human spleen samples were obtained from the ACT Haematology Research Tissue Bank (Canberra Hospital, Canberra, Australia) with informed consent from patients undergoing splenectomies for suspected or known immune thrombocytopenia and/or lymphoma. Spleens selected for this study had no histological evidence of lymphoma. Spleen tissues were kept aseptically on ice and processed within 12 h of removal. The tissues were chopped into small pieces of 0.5-1.0 cm. Cell suspensions were obtained by forcing the tissue through a fine mesh sieve into DMEM with washing by centrifugation at 300g at 4uC for 5 min. For the lysis of red blood cells, cells were resuspended in lysis buffer (140 mM NH 4 Cl, 17 mM Tris base, pH 7.5) at room temperature for 5 min; then cells were washed twice with DMEM by centrifugation at 300g at 4uC for 5 min and resuspended at the desired concentrations.
Preparation of T and B cell-depleted spleen Splenocytes were depleted of T and B cells using MACS methodology (Miltenyi Biotec: North Ryde, NSW, Australia). Biotinylated antibodies specific for hCD19 (HIB18; Biolegend, San Gabriel, CA, USA) and hCD3 (OKT3; Biolegend) were added to 10 7 cells and incubated on ice for 20 min. The cell suspension was then washed twice with labeling buffer (degassed PBS/pH 7.2, 0.5% bovine serum albumin and 2 mM EDTA) by centrifugation at 300g at 4uC for 5 min. The supernatant was discarded, and the cells were resuspended in 20 ml of MACS antibiotin microbeads. The cells were further incubated on ice for 20 min and then washed twice by centrifugation. The cells were resuspended in 500 ml labeling buffer and transferred to a MACS MS column placed in a SuperMACS II Separator (Miltenyi Biotec). The column was washed three times with 3 ml of labeling buffer, and the flow-through cells were collected and washed. This procedure routinely gave .95% purity.
Antibody staining
For antibody staining, cells were washed and resuspended in fluorescence-activated cell sorting (FACS) buffer (DMEM, 0.1% sodium azide, 1% fetal calf serum) at 1310 5 -5310 5 cells/100 ml. A 100 ml volume of cells was plated into a flexible 96-well microtiter plate and centrifuged at 300g at 4uC for 5 min. The cells were resuspended in 25 ml of FACS buffer containing 40 mg/ml of Fc block specific for FccII/IIIR (eBioscience, San Diego, CA, USA) for 15mins on ice before washing by centrifugation and discarding the supernatant. A 25 ml aliquot of diluted primary antibody was added to the cells, which were then incubated in the dark on ice for 25 min. The cells were washed twice with 150 ml of FACS buffer by centrifugation. When required, a 25 ml aliquot of diluted streptavidin conjugate was added to the cells, followed by incubation and washing as above. The cells were resuspended in 70 ml of FACS buffer for flow cytometric analysis. Dead cell exclusion was achieved by the addition of a final concentration of 1 mg/ml propidium iodide (PI) to the cells prior to flow cytometric analysis.
For multicolor staining, cocktails of up to five different primary antibodies were added in the first incubation step. Isotype control antibodies and 'fluorescence minus one controls' were used where appropriate to determine the background binding of antibodies and to set gates. Antibodies and isotype controls were purchased from Biolegend. Primary antibodies specific for hCD11c (clone 3.9), HLA-DR (L243), hCD16 (3G8), hCD1c (L161), hCD123 (6H6), hCD80 (2D10), hCD86 (IT2.2), hCD141 (M80) and hCD14 (HCD14). To stain lineage (Lin) 1 cells, a cocktail of biotinylated antibodies specific for human hematopoietic lineage cells was added to cell suspensions (10 ml per 10 7 cells) and incubated for 10 min on ice. These were specific forhCD3 (OKT3), hCD14 (HCD14), hCD19 (HIB18) and hCD56 (HCD56), which detect mature T cells, B cells, natural killer cells, monocytes/macrophages and granulocytes.
Flow cytometry
Flow cytometry was performed on an LSRII FACS machine (Becton Dickinson: Franklin Lakes, NJ, USA). Voltages, parameters and event counts were set and determined using BD FACSDIVA software (Becton Dickinson). Single-color controls were used to set compensation. FlowJo software (FlowJo, Ashland, OR, USA) was used to analyze the data. In general, cells were gated on the basis of forward scatter and side scatter. Live cells were then gated out by the absence of PI staining. Isotype-matched and 'fluorescence minus one' controls were used to set gates and to distinguish specific antibody binding.
Endocytosis assay
The capacity of cells to endocytose antigen was assessed by in vitro measurement of endocytosis. The cells were washed twice with sDMEM and placed on ice for 10 min. FITC-conjugated ovalbumin (OVA-FITC) (Molecular Probes, Eugene, OR, USA) was added to the cells at a concentration of 2 mg/ml, and the samples incubated at 37 uC for 45 min. Endocytosis was halted by the addition of 100 ml of chilled PBS with 0.1% NaN 3 . The cells were washed three times by centrifugation at 300g at 4uC for 5 min. The supernatant was discarded, and the cells resuspended in FACS buffer for flow cytometric analysis.
Establishment of stromal cocultures
Initially, 5G3 stromal cells were grown to 80%-90% confluency. Co-cultures established by plating T and B cell-depleted splenocytes onto a 5G3 monolayer to study in vitro hematopoiesis and DC development. Cocultures were maintained at 37uC, 5% CO 2 and 95% humidity. Non-adherent cells were collected by gently shaking the flask, followed by removal and replacement of the media at 3-4 day intervals. The cells were then analyzed for cell surface marker expression using antibody staining and flow cytometric analysis at 14, 21 and 28 days.
Statistical analysis
Data are presented as the mean6standard error (s.e.) for sample size n53. Given the small sample sizes, the Wilcoxon Rank Sum Test was used to determine significance (P # 0.05).
RESULTS
The human spleen contains cells resembling murine L-DCs
Human spleens were assessed for the presence of DC subsets using antibody staining and flow cytometric analysis. The initial analysis was performed on T and B cell-depleted splenocytes. Gating on the basis of HLA-DR expression and CD11c or CD11b revealed five subsets that were distinguishable by further staining as DCs or dendritic-like L-DCs. Three subsets were found within the hCD11c 1 HLA-DR 1 population, including hCD16
1 DCs, hCD1c 1 DCs and hCD123 1 pDCs, in line with previous studies 20 ( Figure 1a ). Further analysis revealed that splenic pDCs expressed both hCD86 and hCD80, confirming their mature pDC status (Figure 1a) . hCD141
1 DCs were delineated after lineage (Lin) cocktail antibodies were used to gate out mature Lin 1 cells. Some gated T cells, B cells and myeloid cells expressed low levels of CD11c, so the selected CD11c 1 population in Figure 1c was smaller than that in Figure 1a . Further staining was used to detect HLA-DR, hCD11c and hCD141 (Figure 1c) . A fifth population of DCs was identified within the hCD11c 1 HLA-DR 2 subset. Staining for hCD11b, hCD80 and hCD86 revealed a subset of hCD11c 1 HLA-DR 2 hCD11b 1 hCD80 2 hCD86 1 cells. These were named human L-DCs because of their similarity to the murine L-DC subset described previously 9, 12 ( Figure 1b ). Analysis of monocyte subsets was also performed by flow cytometry. Initially, hCD14 and HLA-DR staining and gating were used to identify the monocytic lineage. Given that human monocytes are HLA-DR 1 , the cells were initially divided by hCD14 and hCD16 expression to delineate three monocyte subpopulations (Figure 1d) 1 DCs; the size of these subsets were not significantly different from one another (Wilcoxon Rank Sum test; P # 0.05) (Figure 2 ). The hCD141 1 DC subset was the smallest population in the spleen and was present in significantly lower numbers than the other DC subsets but was not significantly different in number to any of the monocyte subsets (Figure 2) . Each of the monocyte subsets was found to be present in similar numbers with no significant difference between them, although there were significantly fewer of them compared with the L-DC, hCD16
1 DC, pDC and hCD1
1 DC subsets (Wilcoxon Rank Sum test; P # 0.05) (Figure 2 ).
Murine splenic stroma supports development of human splenic DCs Cocultures were established by plating T and B cell-depleted human splenocytes on top of murine 5G3 stromal cells, and maintaining these cultures for 28 days. This experiment assumes that murine and human splenic stromal cells are similar and that they can act as a niche or cell signaling matrix for in vitro hematopoiesis. Previous studies have demonstrated the ability of the murine 5G3 splenic stroma to support myelopoiesis from hematopoietic stem/progenitor cells present in both murine bone marrow and spleen. 12, 14, 15, 30, 31 Cell growth was monitored, and non-adherent cells were collected and flow cytometrically assessed at 7-day intervals. Live cells were gated, and HLA-DR versus hCD11c staining was used to delineate any dendritic-like cells produced in the cocultures.
Three subsets of cells were identified from these cultures after 21 days: hCD11c hi HLA-DR 1 , hCD11c lo HLA-DR 1 and hCD11c lo HLA-DR 2 cells (Figure 3a) . All subsets expressed hCD11b, hCD80 and hCD86, indicating production of mature dendritic-like cells in these cocultures. The cells produced in these cocultures were large, as evidenced by their high FSC profile. Over time, no hCD123 1 lymphoid cells were observed in any cocultures.
Murine 5G3 stroma can therefore support the development of HLA-DR 1 cells resembling DCs from T and B cell-depleted human spleens over 28 days of coculture. Given that an extended period is necessary, it is thought that these cells arise by hematopoiesis from progenitors present in the enriched spleen cell population. The proportion of hCD11c hi HLA-DR 1 cells produced increased to 30% by 28 days, reflecting the ability of 5G3 stroma to support human DC development. On the basis of high CD11c and MHC-II expression, these cells resemble cDC-like cells, previously reported as a transient early population produced in murine splenic cocultures. 10, 11 These cells disappear after 21-28 days of coculture. The hCD11c lo HLA-DR 2 subset was consistently produced and represented a maximum of 17% of cells over time. The expression of hCD80 and hCD86 on these cells was higher than on the hCD11c 1 DCs, which were further divided into three distinct subsets with hCD11b, hCD11c, hCD16 and hCD1c staining: hCD16 1 DCs, hCD1
1 DCs and plasmacytoid (p) DCs. Expression of hCD80, hCD86 and hCD123 was used to identify pDCs as mature hCD123 2 HLA-DR 2 cells was unable to take up OVA antigen and thus may represent myeloid cells or precursors which are known to be produced transiently in murine cocultures but which disappear after approximately 21 days. While this population is shown in Figure 4 , it is not apparent in Figure 3 , which depicts cells from 28 day cocultures.
DISCUSSION
Previous studies from this lab characterized L-DCs in murine spleens as a novel APC subset that is highly endocytic and capable of cross-presenting antigens to CD8 1 T cells. 9 In an attempt to identify a human counterpart cell type, spleens collected from splenectomized patients were analyzed by antibody staining and flow cytometry. Our study initially identified human L-DCs in the spleen as hCD11b 17,33 pDCs, the major producers of type I interferon, are identified by the expression of hCD123, hCD303 and hCD304. 33 This study has identified hCD1c 1 DCs, hCD16 1 DCs, hCD141 1 DCs and hCD123 1 pDCs in human spleens, which is consistent with previous findings and resembles the subsets found in blood. 20 The expression of hCD86 and hCD80 by hCD123 1 pDCs probably reflects the mature state of these cells in the human spleen.
Human monocytes have been characterized as cells that express HLA-DR, a property that distinguishes them from murine monocytes which are MHC-II ). The phenotype of DC and monocyte subsets in human blood and human spleen appear to be very similar, probably because of the physiological influx and efflux of the same cells between blood and spleen. 36, 37 Previously, murine splenic stroma was demonstrated to support in vitro hematopoiesisby its ability to produce L-DCs from hematopoietic stem cells, as well as cDC-like cells. L-DCs reflect a novel type of APC that is distinguishable by stromadependent development, lack of MHC-II expression, and high endocytic activity, which is consistent with their ability to efficiently cross-present antigens to CD8 T lymphocytes. 10, 11, 38, 39 The in vivo equivalent of L-DCs was later characterized in mouse spleens and shown to have similar phenotype and function. 9 In cocultures of human splenocytes with the 5G3 murine stromal line, several subsets of DC-like cells are produced, and they differ in their expression of HLA-DR and hCD11c. Three subsets were apparent: the hCD11c lo HLA-DR 1 and hCD11c hi HLA-DR 1 subsets of cDC-like cells, which are the majority of cells present in the cocultures, and a minor hCD11c 
HLA-DR
2 subset, which resembles murine L-DCs. All DC subsets produced appear to be activated in the in vitro cultures, as indicated by their expression of both hCD80 and hCD86. Human splenic DC and monocytes Figure 2 Representation of DC and monocyte subsets in human spleen. Splenocytes were analyzed by antibody staining and flow cytometry as described in Figure 1 . Cell frequency was calculated in terms of the number of each cell type in relation to the total number of nucleated cells. Graphs show the means6s.e. for triplicate experiments, which involved the analysis of three individual spleen samples. Statistical significance was assessed using the Wilcoxon Rank Sum test (P # 0.05). No significant differences were detected between the three monocyte subsets or between the three DC subsets of L-DCs, hCD16
1 DCs and pDCs, although each of the monocyte subsets was present in significantly smaller numbers than the three dominant DC subsets (P values not shown). The hCD141
1 DC subset was present in significantly lower numbers than the other four DC subsets. DC, dendritic cell.
Each of these subsets is endocytic and actively takes up FITC-OVA antigen, which demonstrates their capacity to present antigen to T cells. The low yield of cells from human cocultures compared with murine stroma has precluded an analysis of the antigen-presenting capacity of these cells in T cell activation assays. In contrast, cocultures of murine splenocytes with the murine 5G3 stromal line produce higher yields of cells. The subset of hCD11c lo HLA-DR 2 cells appears most similar to L-DCs, with the high endocytic capacity observed in the equivalent murine subset.
It is noteworthy that murine splenic stroma can suffice as a support matrix for hematopoiesis of human splenic hematopoietic progenitors. This is consistent with species conservation of stromal cells, the molecules they produce, and the signaling pathways that support hematopoiesis. It is also important to note the high level of similarity between DC subsets produced in the hybrid human/murine system and those produced in the murine system. While the subsets were present in different relative proportions, they resemble the cDC-like and L-DC-like cells produced in murine cocultures in terms of surface marker phenotype and endocytic capacity. In line with the murine cells, the L-DC-like subset in humans is a CD11c lo subset, which may include both the HLA-DR 2 and the novel HLA-DR 1 subsets, each of which has endocytic capacity. An L-DC equivalent cell in humans may therefore express HLA-DR. A precedent for this hypothesis is exemplified by human monocytes, which are HLA-DR 1 cells, while similar monocyte subsets in mouse are MHC-II Figure 4 Human DCs produced in cocultures are endocytic. Human DCs were produced in murine stromal cocultures over 14 days as described in Figure 3 . They were incubated with 10 mg/ml OVA-FITC at 37uC for 45 min prior to measurement of antigen uptake by flow cytometry. Staining for HLA-DR and hCD11c was used to delineate HLA-DR 1 hCD11c 1 , HLA-DR 1 hCD11c lo , HLA-DR 2 hCD11c lo and HLA-DR 2 hCD11c 2 subsets. Endocytic activity was indicated by greater uptake of OVA-FITC in cells treated at 37uC, compared with control cells treated with OVA-FITC at 0uC. DC, dendritic cell.
